Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot PharmaphorumA unanimous endorsement from FDA advisors brings Moderna's RNA-based seasonal influenza vaccine a step closer to US approval.Infectious DiseaseRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A unanimous endorsement from FDA advisors brings Moderna’s RNA-based seasonal influenza vaccine a step closer to US approval. Infectious Disease Read full story Post navigation Previous: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’Next: Biogen to acquire RayThera for up to $1bn Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
